Pulmonary disease remains a primary source of morbidity and mortality in persons living with HIV (PLWH), although the advent of potent combination antiretroviral therapy (cART) has resulted in a shift from predominantly infectious to noninfectious pulmonary complications.
INTRODUCTION
Pulmonary complications remain a significant source of morbidity and mortality in patients infected with human immunodeficiency virus (HIV). Prior to the advent of combination antiretroviral therapy (cART), pulmonary infections, especially Pneumocystis jiroveci, tuberculosis and community acquired pneumonia, were among the leading causes of death 1 .
With the advent of cART, non-infectious pulmonary complications have become more prevalent in persons living with HIV (PLWH), including chronic obstructive pulmonary disease (COPD), HIV related pulmonary artery hypertension (HIV-PAH) and lung cancer 2;3; 4 . The prevalence of COPD in PLWH in the modern cART era varies by study and by definition, but by spirometry 7-9% of PLWH have clinical obstruction, while one third have respiratory symptoms 5;6 . The prevalence of PAH is 2500 times higher than in the general population, with 0.5% of PLWH estimated to have HIV-PAH, despite effective cART 7 . The incidence of lung cancer is 2.7 times higher in PLWH than in the general population 8;9 . The mechanisms underlying the increased rates of noninfectious lung disease are multifactorial. High rates of tobacco use and intravenous drug use (IVDU) likely contribute, in addition to chronic lung inflammation and subsequent oxidative stress and tissue damage. In this review, we discuss what is currently known about the pathogenesis of COPD, PAH, and lung cancer in PLWH, describe other potential relevant mechanisms of lung damage which may contribute to these diseases ( Figure   1 ), and outline priorities for better understanding the underlying mechanisms in the current cART era.
HIV AND COPD
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COPD is highly prevalent among cigarette smokers, and incidence increases with age 10 .
As PLWH are living longer, high smoking rates contribute to increasing incidence of COPD 3 .
Rates of hospitalization for obstructive lung disease have increased for PLWH in the cART era, and are expected to increase further as the population ages 2 . Several studies have demonstrated that PLWH have higher rates of dyspnea and alterations in pulmonary functions tests (PFT), particularly low diffusing capacity of the lung for carbon monoxide (DLCO), as well as imaging findings of emphysema 4;5;6 . PLWH also appear to have more respiratory symptoms, including dyspnea and cough, than smokers with similar disease burden by PFT criteria 6 .
Inflammation plays an important role in the pathogenesis of COPD in PLWH. Reduced frequencies and absolute numbers of CD4+ T cells are seen in bronchoalveolar lavage (BAL) of PLWH with COPD 12 . These CD4+ T cells, but not CD8+ T cells, demonstrate impaired lung mucosal immunity to HIV, and express high levels of programmed cell death 1 (PD-1), a marker of immune activation and exhaustion. They also express high levels of the Fas death receptor, CD95, and demonstrate increased Fas-dependent activation induced cell death 12 . All of these findings result in progressive loss of CD4+ T cells in the BAL, leading to a profound imbalance in CD4:CD8 ratio and persistent CD8+ T cell alveolitis in HIV-associated COPD. This inflammation leads to the expression of inflammatory cytokines and release of matrix metalloproteinases associated with COPD 13;14 .
HIV-PAH
The association between HIV infection and pulmonary hypertension was recognized early on in the AIDS epidemic 15 . Although cART may have decreased the incidence of HIV-PAH M A N U S C R I P T
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and has been shown to partially reverse pulmonary hypertension in a small number of PLWH 7 , PAH remains a significant clinical complication in PLWH, particularly as life expectancy increases. Symptoms and signs usually present late, and half of patients with HIV-PAH die during a median follow-up period of 8 months 16 , although a more recent study demonstrated that three year survival is 72% in patients treated with both cART and specific PAH therapy 17 .
Specific therapy for PAH appears to improve hemodynamic parameters more than cART, as cART has minimal effect even if it is instituted early in disease 18 . Approximately two-thirds of deaths are attributed to pulmonary hypertension rather than complications of immune deficiency 16;15 . CD4+ T cell count is the only independent predictor of survival, and patients with HIV-PAH have poorer survival rates when compared to uninfected patients with PAH 15;16 .
Direct HIV infection, substance abuse and chronic inflammation are particularly important in the development of HIV-PAH 19 . Chronic exposure to HIV viral proteins in the lung (e.g. Nef, Tat, gp120), as well as HIV-induced immune dysregulation, contribute to pulmonary vascular disease, particularly through an impact on pulmonary endothelial cells (EC). HIV Nef protein co-localizes with EC in PAH-like plexiform lesions in animal models 20 . Substance abuse also plays a significant role. In animal models, cocaine increases proliferation of pulmonary vascular endothelial cells and morphine contributes to vascular disease and oxidant stress 21;22 . downregulate the p53 tumor suppressor gene 26 . Although cART can have genotoxic effects, no association has been found between cART and lung cancer risk, and early cART is associated with decreased risk 27 .
HIV AND LUNG CANCER
COMMON MECHANISMS OF LUNG DISEASE IN PLWH
The cause of higher rates of noninfectious lung complications in PLWH is multifactorial.
PLWH demonstrate evidence of chronic lung inflammation from a variety of causes, including direct effects of HIV, cART, illicit drug use, immunodeficiency, opportunistic infections, and alterations in the lung microbiome. The potential mechanisms by which these factors contribute both specifically and generally to HIV-PAH, COPD and lung cancer are outlined in Figure 1 .
SMOKING AND HIV
The prevalence of smoking in PLWH ranges from similar to twice that of the general population depending on the comparison group. The largest study demonstrated that 42% of PLWH are current smokers, compared to 21% of the general population 28 . In contrast, when the comparison group consists of uninfected subjects with a high smoking prevalence, such as the Veterans' Aging Cohort Study (VACS) or Multicenter AIDS Cohort Study (MACS) cohort which matches patients with similar risk profiles, smoking rates are more similar in the two M A N U S C R I P T
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groups, although PLWH still have higher rates 29;30 . Compared to non-smokers, PLWH who smoke have higher levels of inflammatory markers, including soluble CD14 and expression of HLA-DR on both CD8+ and CD4+ T cells 31;32 . Cigarette smoking has been linked to increased rates of mortality due to cardiovascular disease, COPD, pneumonia, and lung cancer 29 . If HIV is treated, modeling studies suggest that PLWH who smoke lose over six years of life expectancy, more than that lost to HIV infection 33 .
PLWH are less likely to quit than the general population (32% vs 52%) 28 . Multiple factors are associated with continued smoking in PLWH, including higher rates of other substance abuse, psychiatric disorders, low socioeconomic status and poor access to care 34 .
Perhaps because of multiple competing interests and limited time to address medical issues, counseling on smoking cessation happens less frequently for PLWH than the general population 35 .
Despite clear evidence that cigarette smoking contributes to significant disease in PLWH, most studies of smoking related illness are poorly controlled for the impact of cumulative exposure to cigarette smoke, and control only for smoking status, i.e. current, past or nonsmoking status. A recent study clearly demonstrated that both cumulative pack-year smoking history and time since smoking cessation are more strongly associated with lung and heart disease than smoking status 36 , suggesting that a true understanding of the role of cigarette smoke as a pathogenic factor in HIV-associated lung disease will require better collection of data on total tobacco exposure.
HIV pathology in the lung is driven by infection of CD4+ T cells and alveolar macrophages, which play an important role in the development of pulmonary disease 37;38 .
Animal models demonstrate that the lungs and intestines harbor the highest levels of simian immunodeficiency virus (SIV) among non-lymphoid tissues 39 , and early in infection, CD4+ T cells are rapidly depleted from mucosal sites 37;40 . Recent data suggests that lung epithelium can also be directly infected by HIV, especially CXCR4-tropic strains associated with advanced disease. HIV infection results in integration of the viral genetic material into the cellular genome. This integration may change gene expression and immune response 41 . Expression of viral proteins, such as Tat, increases inflammation and oxidative stress in animal models 42 . HIV infection alters the function of airway epithelial cells by impairing cell-cell adhesion and increasing the expression of inflammatory mediators 43 . Thus HIV infection contributes to lung disease by both direct effects of infection and through modulation of systemic inflammation and immunodeficiency.
COMBINATION ANTIRETROVIRAL THERAPY (cART)
Treatment of HIV-1 infection with cART has generally been associated with improved outcomes 29 , especially in reduction of infectious pulmonary complications. Its influence on non-infectious pulmonary complications has been more controversial. Protease inhibitor use has been linked to an increased incidence of malignancy, although not lung cancer specifically 27 . Older antiretrovirals may have had genotoxic effects which contribute to this increased risk. Although one study demonstrated that cART increased the risk of COPD 44 , the pulmonary substudy embedded in the large Strategic Timing of Antiretroviral Therapy (START) trial demonstrated that the timing of ART had no effect on COPD progression 45 Together with tobacco exposure, this combination of cellular activation and immune dysfunction contributes to the pathogenesis of lung disease.
HIV ASSOCIATED PULMONARY INFECTIONS AND THE MICROBIOME
Recent studies have revolutionized our understanding of the role the microbiome plays in health and disease 54 . Although the microbial community is smaller in the lung than in the gut, it is clear that it is diverse and modulated by disease 55;56 . Pulmonary flora is modulated by inhaled corticosteroids or bronchodilator use 56 HIV pathogenesis is characterized by gastrointestinal CD4+ T cell depletion and a compromised mucosal barrier, leading to microbial translocation, endotoxemia and systemic immune activation 40 . Shifts in the gut microbiome have also been seen in PLWH 63;11 , although the extent to which this is due to HIV infection versus other factors, such as sexual preference, is still unclear 64 . In addition to systemic immune activation, which appears to be related to gastrointestinal pathology, changes in the gut microbiome may have a particular influence on pulmonary disease. Several epidemiologic studies, as well as studies in murine models, have demonstrated a correlation between susceptibility to pulmonary infections, allergic airway disease and an altered fecal microbiome 65 . There is an epidemiologic correlation between COPD and inflammatory bowel disease 66 , which may be smoking related, but may also be due to shifts in the microbiome, inflammation or modulation of matrix metalloproteinases 67 .
OXIDATIVE STRESS
The lung is at particular risk of damage due to excessive oxidative stress, because it is directly exposed to oxygen, inhaled pollutants, and microbes that produce pro-oxidant reactive oxygen and nitrogen species. Higher levels of markers of oxidative stress and lower levels of antioxidant glutathione are found in smokers, as well as patients with COPD and/or HIV 68 .
Oxidative stress is worsened during acute exacerbations of COPD 69 . HIV infection is associated with high rates of oxidative stress 68 
